v3.25.4
Segment Information
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment Information

17. Segment Information

The Company operates under one reportable business segment to advance the development, manufacturing and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The determination of a single reportable business segment is consistent with the consolidated financial information regularly provided to the Company’s CODM. All of the Company's long-term assets and operations are located in the United States. The Company’s CODM is its Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance, including comparing actual results to budgets and forecasts to assess variances, identify trends, and guide strategic planning.

In addition to the significant expense categories included within the consolidated statements of operations, the below disaggregated amounts comprise significant research and development and general and administrative expenses. These expenses consist of (1) clinical, manufacturing and research contracts for research and development programs, (2) personnel-related expenses, including salaries, benefits and share-based compensation, (3) professional fees, including third-party costs for goods and services such as lab supplies and contract research, and legal and other professional expenses, and (4) facility and other overhead expenses, including depreciation, occupancy, travel, insurance and other costs.

 

 

 

Year Ended December 31

 

(in thousands)

 

2025

 

 

2024

 

Research and development

 

 

 

 

 

 

  Clinical, development and licensing expenses

 

$

3,898

 

 

$

4,549

 

  Personnel related expenses

 

 

2,103

 

 

 

3,026

 

  Professional fees

 

 

1,224

 

 

 

1,733

 

  Facility and other overhead expenses

 

 

1,154

 

 

 

1,272

 

     Total research and development

 

 

8,379

 

 

 

10,580

 

General and administrative

 

 

 

 

 

 

  Personnel related expenses

 

 

5,611

 

 

 

3,454

 

  Professional expenses

 

 

4,970

 

 

 

4,828

 

  Facility and other overhead expenses

 

 

1,551

 

 

 

1,657

 

     Total general and administrative

 

$

12,132

 

 

$

9,939

 

 

All of the Company's long-term assets and operations are located in the United States.